Neisseria meningitidis Group A IgG1 and IgG2 Subclass Immune Response in African Children Aged 12-23 Months Following Meningococcal Vaccination
- PMID: 26553689
- PMCID: PMC4639486
- DOI: 10.1093/cid/civ505
Neisseria meningitidis Group A IgG1 and IgG2 Subclass Immune Response in African Children Aged 12-23 Months Following Meningococcal Vaccination
Abstract
Background: A group A meningococcal conjugate vaccine, PsA-TT, was licensed in 2010 and was previously studied in a phase 2 clinical trial to evaluate its safety and immunogenicity in African children 12-23 months of age.
Methods: Subjects received either PsA-TT; meningococcal group A, C, W, Y polysaccharide vaccine (PsACWY); or Haemophilus influenzae type b conjugate vaccine (Hib-TT). Forty weeks following primary vaccination, the 3 groups were further randomized to receive either PsA-TT, one-fifth dose of PsACWY, or Hib-TT. Group A-specific immunoglobulin G (IgG) subclass response was characterized using an enzyme-linked immunosorbent assay.
Results: The predominant IgG subclass response, regardless of vaccine, was IgG1. One month following primary vaccination, the geometric mean concentrations (GMCs) of IgG1 and IgG2 in the PsA-TT group were 21.73 µg/mL and 6.27 µg/mL, whereas in the PsACWY group the mean GMCs were 2.01 µg/mL and 0.97 µg/mL, respectively (P < .0001). Group A-specific IgG1 and IgG2 GMCs remained greater in the PsA-TT group than in the PsACWY group 40 weeks following primary vaccination (P < .0001). One week following revaccination, those given 2 doses of PsA-TT had the greatest IgG1 and IgG2 GMCs of 125.23 µg/mL and 36.12 µg/mL, respectively (P = .0008), and demonstrated a significant increase in IgG1:IgG2 mean ratio, indicative of the T-cell-dependent response associated with conjugate vaccines.
Conclusions: Vaccination of African children aged 12-24 months with either PsA-TT or PsACWY elicited a predominantly IgG1 response. The IgG1:IgG2 mean ratio decreased following successive vaccination with PsACWY, indicating a shift toward IgG2, suggestive of the T-cell-independent immune response commonly associated with polysaccharide antigens.
Clinical trials registration: SRCTN78147026.
Keywords: IgG subclass; Neisseria meningitidis; meningococcal; vaccination.
© The Author 2015. Published by Oxford University Press for the Infectious Diseases Society of America.
Similar articles
-
Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans.N Engl J Med. 2011 Jun 16;364(24):2293-304. doi: 10.1056/NEJMoa1003812. N Engl J Med. 2011. PMID: 21675889 Clinical Trial.
-
Safety and immunogenocity of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C-tetanus-toxoid conjugate vaccine in healthy Chinese children aged 6 months to 5 years old.Hum Vaccin Immunother. 2015;11(5):1120-8. doi: 10.1080/21645515.2015.1033592. Hum Vaccin Immunother. 2015. PMID: 25833163 Free PMC article. Clinical Trial.
-
Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants.Pediatr Infect Dis J. 2010 Jan;29(1):48-52. doi: 10.1097/INF.0b013e3181c3ce88. Pediatr Infect Dis J. 2010. PMID: 20035207 Clinical Trial.
-
MenHibrix: a new combination meningococcal vaccine for infants and toddlers.Ann Pharmacother. 2014 Mar;48(3):404-11. doi: 10.1177/1060028013514375. Epub 2013 Dec 18. Ann Pharmacother. 2014. PMID: 24353263 Review.
-
Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV).Pediatr Infect Dis J. 2009 Apr;28(4 Suppl):S97-S108. doi: 10.1097/INF.0b013e318199f61b. Pediatr Infect Dis J. 2009. PMID: 19325452 Review.
Cited by
-
Impact of age and vaccination history on long-term serological responses after symptomatic B. pertussis infection, a high dimensional data analysis.Sci Rep. 2017 Jan 16;7:40328. doi: 10.1038/srep40328. Sci Rep. 2017. PMID: 28091579 Free PMC article.
-
Kinetics of maternally-derived serogroup A, C, Y and W-specific meningococcal immunoglobulin G in Malian women and infants.Vaccine. 2019 Apr 24;37(18):2477-2481. doi: 10.1016/j.vaccine.2019.03.045. Epub 2019 Apr 2. Vaccine. 2019. PMID: 30952500 Free PMC article. Clinical Trial.
-
Safety and immunogenicity of conjugate quadrivalent meningococcal vaccination after hematopoietic cell transplantation.Blood Adv. 2018 Jun 12;2(11):1272-1276. doi: 10.1182/bloodadvances.2018018911. Blood Adv. 2018. PMID: 29871892 Free PMC article. Clinical Trial.
References
-
- Greenwood B. Manson lecture. Meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg 1999; 93:341–53. - PubMed
-
- Rijkers GT, Sanders EA, Breukels MA, Zegers BJ. Infant B cell responses to polysaccharide determinants. Vaccine 1998; 16:1396–400. - PubMed
-
- Borrow R, Goldblatt D, Andrews N et al. . Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom. J Infect Dis 2002; 186:1353–7. - PubMed
-
- Kelly DF, Snape MD, Clutterbuck EA et al. . CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells. Blood 2006; 108:2642–7. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous